Sökning: onr:"swepub:oai:DiVA.org:kth-236553" >
Development of an o...
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
-
- Vorobyeva, Anzhelika (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Westerlund, Kristina (författare)
- KTH,Proteinvetenskap,KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden
-
- Mitran, Bogdan (författare)
- Uppsala universitet,Theranostics
-
visa fler...
-
- Altai, Mohamed (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Rinne, Sara (författare)
- Uppsala universitet,Theranostics
-
- Sörensen, Jens (författare)
- Uppsala universitet,Radiologi,Uppsala Univ Hosp, Med Imaging Ctr, Uppsala, Sweden
-
- Orlova, Anna, 1960- (författare)
- Uppsala universitet,Theranostics,Science for Life Laboratory, SciLifeLab,Uppsala Univ, Sci Life Lab, Uppsala, Sweden
-
- Tolmachev, Vladimir (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Eriksson Karlström, Amelie (författare)
- KTH,Proteinvetenskap,KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2018-06-25
- 2018
- Engelska.
-
Ingår i: Scientific Reports. - : Nature Publishing Group. - 2045-2322. ; 8:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://www.nature.c...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Affibody molecules are engineered scaffold proteins, which demonstrated excellent binding to selected tumor-associated molecular abnormalities in vivo and highly sensitive and specific radionuclide imaging of Her2-expressing tumors in clinics. Recently, we have shown that peptide nucleic acid (PNA)-mediated affibody-based pretargeted radionuclide therapy using beta-emitting radionuclide 177Lu extended significantly survival of mice bearing human Her2-expressing tumor xenografts. In this study, we evaluated two approaches to use positron emission tomography (PET) for stratification of patients for affibody-based pretargeting therapy. The primary targeting probe ZHER2:342-SR-HP1 and the secondary probe HP2 (both conjugated with DOTA chelator) were labeled with the positron-emitting radionuclide 68Ga. Biodistribution of both probes was measured in BALB/C nu/nu mice bearing either SKOV-3 xenografts with high Her2 expression or DU-145 xenografts with low Her2 expression. 68Ga-HP2 was evaluated in the pretargeting setting. Tumor uptake of both probes was compared with the uptake of pretargeted 177Lu-HP2. The uptake of both 68Ga-ZHER2:342-SR-HP1 and 68Ga-HP2 depended on Her2-expression level providing clear discrimination of between tumors with high and low Her2 expression. Tumor uptake of 68Ga-HP2 correlated better with the uptake of 177Lu-HP2 than the uptake of 68Ga-ZHER2:342-SR-HP1. The use of 68Ga-HP2 as a theranostics counterpart would be preferable approach for clinical translation.
Ämnesord
- NATURVETENSKAP -- Kemi (hsv//swe)
- NATURAL SCIENCES -- Chemical Sciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas